Stock GOSS GOSSAMER BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
0.7328 USD +1.78% Intraday chart for Gossamer Bio, Inc. +0.18% -19.69%
05-07 Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
CI
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
RE
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine
CI
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023
CI
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Gossamer Bio Inc. Announces FDA has Placed a Partial Clinical Hold on All Trials of GB5121 in Response to Serious Adverse Events
CI
GOSSAMER BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH
CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Gossamer Bio Q2 Loss Narrows
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GOSS Stock
  4. News Gossamer Bio, Inc.
  5. Highlights